Press "Enter" to skip to content

Oral Novo Nordisk diabetes drug poses no more heart risk than placebo: study

Patients with type 2 diabetics and either heart disease or at high risk for heart problems who received the drug semaglutide in pill form had a combined rate of heart attack, stroke or heart-related death of 3.8% compared with 4.8% for placebo, successfully demonstrating non-inferiority.

Original source: https://health.economictimes.indiatimes.com/news/pharma/oral-novo-nordisk-diabetes-drug-poses-no-more-heart-risk-than-placebo-study/69753886?utm_source=RSS&utm_medium=ETRSS

Also Read:   Roche Pharma India expands partnership with Cipla for key oncology medicines